"Chengdu" new crown vaccine was approved in Mexico to conduct phase I/II clinical trials

The reporter was informed today that the Mexican pharmaceutical supervision department has issued a license to approve the reorganized mutant new coronary vaccine (SF9 cells) developed by Chengdu Wesk Biomedical Co., Ltd./Sichuan University Huaxi Hospital.

This study is a random, blind, and controlled research. The purpose of the research is: evaluating the basic immune group of this product to complete the new crown vaccine, or the MRNA vaccine, or adenovirus vaccine, and enhance the safety and immunogenicity of vaccination. Studies will recruit people 18 years and above, who have completed the above -mentioned technical routes of new crown vaccines, and conduct sequential immunization clinical studies. The company will complete the first batch of subjects to join in the near future.

When OMICRON (Omicron) mutated strains just appeared at the end of 2021, Wesk creatures quickly acted and actively promoted the study of the strains, cell matrix, and process quality of new coronary virus vaccines (SF9 cells). The sub -unit vaccine antigen is designed, which can be assembled as a stable protein particles. The large -scale production of vaccines adopts international advanced insect cell protein expression technology, and cooperates with WGA01 (MF59 sample agent) that can induce more immune response.

At present, the epidemic of new coronary pneumonia is still spreading globally, and Omitron mutant BA.4 and BA.5 have become the world's major popular strains. The vaccine for Omitron mutations BA.4, BA.5 and BA.2.12.1, as well as mutation strains such as Beta (Beta), Gamma (gamma), Delta (Delta) can induce high neutralization and neutralization. The antibody titular, suggesting that the vaccine is a general -purpose new crown vaccine for a variety of mutant strains.

At present, Wesk Bio has submitted a new type of coronary virus vaccine (SF9 cell) I/II clinical trial application in domestic and Japan. The approval of the clinical trials of the phase I/II phase of Mexico will further accelerate the research and development process of reorganizing the new Coronatte vaccine (SF9 cells) and contribute to the global anti -new coronary pneumonia epidemic.

Chengdu Daily Jinguan News reporter Yang Su Picture Chengdu Wesk Biomedical Co., Ltd. provides responsible editor He Qixie Internship Editor Lu Yarui

- END -